Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2013 Nov;33(11):4951-7.

Gut peptide profile and chemotherapy-associated dyspepsia syndrome in patients with breast cancer undergoing FEC60 chemotherapy.

Author information

  • 1Laboratorio di Fisiopatologia della Nutrizione, I.R.C.C.S. Saverio De Bellis, via Turi 27, 70013 Castellana Grotte, Bari, Italy. francesco.russo@irccsdebellis.it.

Abstract

AIM:

The association of motilin, ghrelin, leptin, gastrin, pepsinogen (PG) I and II with cancer chemotherapy-associated dyspepsia syndrome (CADS) was investigated in 35 patients with breast cancer receiving first cycle of 5-fluorouracil, cyclophosphamide, epirubicin (FEC60) chemotherapy.

PATIENTS AND METHODS:

The onset of dyspeptic symptoms on days 3 and 10 after chemotherapy identified patients with and without CADS. Gastrointestinal symptoms were scored with the Gastrointestinal Symptom Scoring Rate (GSRS) questionnaire. Gastrointestinal peptides were evaluated by enzyme-linked immunosorbent assay.

RESULTS:

Twenty-one patients (60%) had CADS. The area under the curve (AUC) of ghrelin was higher, whereas that of PGI, PGII and motilin were lower in patients with CADS compared to those without. In patients with CADS, the AUC of PGI and PGII negatively correlated with the GSRS indigestion cluster.

CONCLUSION:

Impairment of gastrointestinal motility suggested by low motilin concentrations and mucosal damage mirrored by an increase of ghrelin seem to be involved in the onset of CADS in patients during chemotherapy for breast cancer.

KEYWORDS:

Adjuvant chemotherapy; breast cancer; dyspepsia; gastrin; ghrelin; leptin; motilin; pepsinogens

PMID:
24222135
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk